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license (http://creativecommons.org/Abstract Medical and scientific research in the field of pulmonary arterial hypertension (PAH)
in adults with congenital heart disease (ACHD) has gradually become globalized, inclusive and
collaborative over the past few years. The education of physicians, health administrators and
patients on congenital heart disease (CHD), specifically in the field of PAH, is of paramount
importance. It is also crucial for ACHD patients with PAH to be followed in tertiary centers
and to benefit from a multidisciplinary approach. Shared care models dictate a closer collab-
oration between tertiary expert centers and local non-specialist services, as well as
networking between expert physicians in CHD and PAH and geneticists/epidemiologists, with
the inclusion of PAH-CHD patients in national and international registries with a detailed geno-
typic/phenotypic characterization.
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vival prospects and an improved quality of life for patients
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Figure 1 Recommendations for shunt closure based on the
baseline indexed pulmonary vascular resistance (PVRi).
Pulmonary arterial hypertension in congenital heart disease 219studies excluded patients with Eisenmenger syndrome,
namely, PAH related to bidirectional or right-to-left
congenital heart shunts. Due to similarities with idio-
pathic PAH, PAH in adult patients with congenital heart
disease (ACHD) and previous reparative surgery has been
the only permissive ACHD subgroup included in major PAH
trials. This ACHD subgroup represents a small proportion of
PAH patients in such large PAH studies (less than 10% of the
total population enrolled). It is, therefore, necessary to
invest further in clinical research and collaboration be-
tween expert ACHD centers and address areas that are
controversial and lack evidence.
Since 1897, when Viktor Eisenmenger first described a
typical case of a syndrome that would later bear his name
and provided a detailed anatomical and clinical description
of a cyanotic male patient with a ventricular septal defect,
significant academic advances in our understanding and
management of PAH in ACHD have occurred. However,
there are still numerous questions to be addressed.1,2 First,
we need robust data on the epidemiology of PAH in ACHD.
For instance, the exact number of patients with Eisen-
menger syndrome worldwide remains unknown.3 Previous
studies have based the diagnosis on echocardiography and
included patients from previous eras in which early repar-
ative or palliative surgery of congenital cardiac disease was
not always available. This may still be a problem in some
parts of the developing world. Moreover, little is known
about the natural history and optimal management of pe-
diatric patients with PAH, who have been reported to have
a worse outcome compared with their adult counterparts.4
Research is also required to understand how to best func-
tionally assess patients with Down syndrome who consti-
tute, at present, a significant proportion of the
Eisenmenger syndrome cohort (up to a third).5 Although the
current guidelines and recommendations have proposed
criteria for shunt closure in patients with net left-to-right
shunting and PAH (Fig. 1), they still represent a manage-
ment dilemma.6 There are still unresolved issues, such as
the management of patients with borderline pulmonary
vascular resistance at rest; the long-term impact of
reversibility studies using pulmonary vasodilators for the
purpose of assessing operability; and the employment of a
staged treatment approach, such as a partial defect closure
with one-way flaps or the creation of a small fenestration in
the patch repair that would permit a “pop-off” valve.
Critically, the decision to intervene and close a defect
should not be solely based on the procedural feasibility and
technical aspects, as such a decision may compromise the
long-term prospects for these patients by converting the
disease to a more aggressive form of PAH. We submit that
there is an urgent need for patients with PAH and left-to-
right shunts to be followed in tertiary academic centers,
where long-term follow-up clinical studies or international
registries are present, as well as for expert opinions in this
population of borderline patients. In general, with regards
to PAH and left-to-right shunts, patients should only un-
dergo defect closure if a certain and long-standing benefit
from such intervention can be anticipated. The exact cir-
cumstances in which this can be sufficiently guaranteed are
currently uncertain, and either surgical or catheter therapy
may have long-term detrimental effects in these patients.
Moreover, we need to gather expert opinions on the safetyand efficacy of a “treat and repair” approach in this pop-
ulation (that is, to treat patients with PAH-specific therapy
and, if they respond well, to then consider defect closure),
as there is no substantive evidence to support this approach
at the present time.7
The varying responses of the pulmonary vascular bed to
similar hemodynamic stimuli implies different underlying
predispositions to pulmonary vascular disease relating to
unknown genetic factors.5 This may also be supported by
the presence of different phenotypes/genotypes of pa-
tients with Down syndrome and of patients with ASD-
related PAH.8 Furthermore, some patients develop PAH
later in life, even after timely early childhood repair of a
defect and even in the absence of significant residual he-
modynamic lesions (e.g., PAH in the setting of transposition
of the great arteries). Much work is needed to understand
the genetic and molecular mechanisms underlying the
development of PAH, both in CHD and other types of dis-
ease, leading to a common endpoint of a histologically
deranged pulmonary vascular bed (Table 1). Therefore,
there is a need for a closer collaboration between CHD and
PAH physicians and geneticists/epidemiologists towards
this end, with the inclusion of PAH-CHD patients in national
and international registries and with a detailed genotypic/
phenotypic characterization.
The traditional belief that survival prospects are far
superior in ACHD patients with PAH compared to other PAH
etiologies is not always supported by recent studies.9,10 In
contrast, there is now evidence that at least patients at the
extreme end of the spectrum of ACHD-PAH, namely, pa-
tients with Eisenmenger syndrome, respond well and safely
to PAH specific therapy and demonstrate improved hemo-
dynamics, 6-minute walking test distance, functional class
and survival prospects.11 It is therefore appropriate to treat
Table 1 Pulmonary hypertension in congenital heart disease. Prevalence and pathophysiology.
Location of defect Type of defect Prevalence of PAH* Pathophysiology
Shunt at atrial level Atrial septal defects 8% in secundum ASDs
7% in primum ASDs
Volume overload is the initial stimulus.
Presents later in life. Development
of PAH is idiosyncratic (possible genetic
predisposition).
Maladaptive response of the RV
resembles that of idiopathic PAH,
with dilation and progressive systolic
dysfunction. Prognosis is worse than
that of post-tricuspid shunts.











7% in DILV, 17% in
DORV, 11% in other UH
Volume and pressure overload early
in life (in large shunts).
Lower right atrial pressures suggest
better RV diastolic properties.
Higher prevalence of patients with
Down syndrome (especially AVSD).
Shunt at arterial level Aortopulmonary window
Persistent ductus arteriosus
Truncus arteriosus







Same pathophysiology with shunts at
the ventricular level.
Aortopulmonary shunts and
collaterals may cause segmental
hypertension, which is a challenging
diagnosis.
*Retrospective echocardiographic data from a Dutch registry.22
PAH: pulmonary arterial hypertension, NA: not available, DILV: double inlet left ventricle, DORV: double outlet right ventricle, UH:
univentricular heart, RV: right ventricle, AVSD: atrioventricular septal defect.
220 G. Giannakoulas, M.A. Gatzoulisthese patients with ACHD-PAH proactively as with patients
with idiopathic PAH. Although the positive impact of dis-
ease targeting therapies in ACHD patients with PAH is now
well recognized and has been confirmed by recent studies,
there are areas of uncertainty, such as the initiation of
medical therapy early in the course of the disease (WHO
class I/II), optimal use of combination medical therapy
(upfront versus sequential), administration of parenteral
prostanoids and use of novel treatments based on alterna-
tive pathophysiology pathways, which are prominent in PAH
in ACHD (e.g., inflammation). Furthermore, disease tar-
geting therapies in ACHD patients with PAH and net left-to-
right shunts have not been fully explored. Theoretically,
the administration of targeted PAH therapies to further
augment pulmonary blood flow may accelerate the pro-
gression of pulmonary vascular disease. Physicians have
remained somewhat hesitant to treat such patients,
although data from the Bologna group suggest that they
respond well to PAH-specific therapy in an intention-to-
treat protocol. Other unexplored areas are the adminis-
tration of targeting therapies in patients with complex
disease, such as those with univentricular heart and PAH, as
these patients have been excluded from major trials thus
far, as well as in patients with segmental PAH.12
Although the treatment recommendation for PAH-ACHD
has recently been published (Table 2),13 it is currently un-
clear as to whether these patients should be treated with a
goal-oriented strategy (as has been proposed for idiopathic
PAH) and what these treatment targets should be. The
optimal use of antiplatelet and oral anticoagulation ther-
apy in Eisenmenger patients, who are prone to both
thrombosis and bleeding, also remains unknown.14Furthermore, additional data are needed on the role of
physical rehabilitation, exercise prescription, iron supple-
mentation, long-term oxygen therapy, and so on.15 Finally,
it remains unclear which clinical endpoints should be used
in trials on PAH-ACHD, especially in adult patients with
Eisenmenger syndrome.16 In fact, the relative stability of
adults with Eisenmenger syndrome, in some, up to the
fourth decade of life, makes hard endpoints, such as mor-
tality or morbidity, difficult to implement in such an un-
common disease. Therefore, there is a need to strengthen
the networking between ACHD-PAH expert centers, build
multicenter collaborations and facilitate randomized trials
with the aim of increasing the sample size. Finally, in line
with the PAH paradigm, harder study endpoints that
represent clinical parameters, beyond those of an
improvement in exercise capacity, should be validated
preferably if they reflect the quality of life and overall
clinical outcome.17
Lately, the utilization of PAH-specific therapies in pop-
ulations beyond the Eisenmenger complex has gained
increased interest. Indeed, a large patient group, which
remains untreated, is the Fontan population. These pa-
tients, strictly speaking and according to the international
guidelines for PAH, do not meet the diagnostic criteria for
PAH; however, recent evidence suggests abnormal vascu-
lature in the Fontan circulation of chronic low cardiac
output and a relatively increased pulmonary vascular
resistance, which in theory, could be modulated by PAH-
specific therapy. Although recent controlled randomized
trials have shown that bosentan or other pulmonary vaso-
dilators have small but significant beneficial effects on
important cardiopulmonary measures,18 there is still
Table 2 Treatment of pulmonary hypertension in congenital heart disease.
PAH targeted therapy Bosentan is recommended in WHO-FC III patients with Eisenmenger syndrome
Other ERAs, PDE-5 inhibitors and prostanoids should be considered in patients with
Eisenmenger syndrome
A combination drug therapy may be considered in patients with Eisenmenger syndrome
The use of calcium channel blockers is not recommended in patients with Eisenmenger syndrome
Anticoagulation In the absence of significant hemoptysis, oral anticoagulation may be considered in patients
with pulmonary arterial thrombosis or signs of heart failure
Oxygen The use of supplemental oxygen therapy should be considered in cases in which it
produces a consistent increase in arterial O2 saturation and reduces symptoms
Phlebotomy Routine phlebotomy should be avoided. If symptoms of hyperviscosity are present, phlebotomy
with isovolumic replacement should be considered, usually when the haematocrit is >65%
Iron The use of a supplemental iron treatment may be considered in patients with low ferritin
plasma levels
Other general measures Dehydration should be avoided
Pregnancy is contraindicated
Immunization of PAH patients against influenza and pneumococcal infection is recommended
Psychosocial support is recommended in ACHD PAH patients
Supervised exercise training should be considered in physically deconditioned patients,
while excessive physical activity that leads to distressing symptoms is not recommended
In elective surgery, epidural rather than general anesthesia should be preferred whenever possible
Pulmonary arterial hypertension in congenital heart disease 221uncertainty, and future research is needed to identify
which Fontan patients are true responders and whether an
earlier rather than a later treatment initiation will lead to a
maximum efficacy effect.
There are inherent difficulties in performing randomized
controlled trials in the field of ACHD-related PAH, which are
needed to overcome areas of controversy and those that
lack evidence. Blinding is extremely difficult, and it is not
clear how such trials can be funded in the future unless a
strong case for greater cost-effectiveness against the
standard therapeutic protocols can be supported or the
industry develops an intense interest. Therefore, there is a
need for collaborative clinical research between specialist
centers, to organize international registries and to
strengthen expert opinion.19 It is paramount for ACHD pa-
tients with PAH to be followed in tertiary centers and
benefit from a multidisciplinary approach, including areas
such as complex electrophysiology, anesthesia,Table 3 Future global prospects in the field of PAH associated
Provide an early diagnosis and timely repair of congenital heart l
developing countries (thus preventing the development of PAH
Improve transition patterns in tertiary centers from pediatric car
Patients lost to follow-up should be brought back into expert care
class III or greater
Develop registries/genetic databases to elucidate the pathophysi
despite early intervention)
Organize multicenter collaborations between centers of excellen
developing countries
Organize collaborations and alliances between research organizat
Support the development of national/international registries (e.g
parenteral prostanoids in CHD-related PAH, other)
Study pathophysiology pathways (e.g., inflammation) to develop
Encourage the design of multicenter randomized trials in new te
syndrome, potential role of supplemental oxygen, targeted PAhematology, gynecology, high-risk obstetrics, dentistry, and
so on.20 The improvement of referral patterns will lead to
diminishing numbers of patients who are lost to follow-up
or may present late with advanced disease, while at the
same time, a closer collaboration between CHD and PAH
centers will eventually improve the clinical outcome of this
population. Patients who are lost to follow-up globally
should be referred back to tertiary healthcare centers and
be offered PAH-advanced therapy, especially those of WHO
class III or greater. Globally, the inappropriate practices of
the past, such as routine venesections and absolute exer-
cise restriction should be abandoned. Education in ACHD,
specifically in the field of PAH, is a key task.21 There is
clearly a need for a wider engagement, including education
on PAH-ACHD for a broader healthcare professional audi-
ence, with direct links to tertiary centers to achieve
optimal patient care in this complex area, minimizing risks
through safety mechanisms and avoidance of pitfalls. Onewith CHD.
esions that are prone to PAH development, especially in
)
e
and offered PAH-specific therapy when they are in functional
ologic mechanisms (e.g., patients who develop late PAH
ce in developed countries and improve the infrastructure in
ions and scientific societies that share the common interests
., anticoagulation and hemoptysis in Eisenmenger patients,
novel therapeutic modules
rritories (e.g., early, targeted PAH treatment in Eisenmenger
H therapy in the Fontan population)
222 G. Giannakoulas, M.A. Gatzoulisof the future aims should be a coordinated effort in support
of PAH-ACHD in developing countries through a greater
allocation of resources, with the collaboration and support
of the PAH-CHD community worldwide, targeting a better
awareness and an earlier diagnosis, followed by a wider
availability of targeted-PAH therapies.
Medical and scientific research in this field over the past
few years has gradually become more globalized, inclusive
and collaborative. Looking ahead, national and interna-
tional registries should provide a better understanding of
the epidemiology, genetics, natural history, and therapeu-
tic outcomes of the heterogeneous PAH population
(Table 3). The registries should focus on areas such as the
safety and efficacy of anticoagulation, clinical significance
and management of hemoptysis, pregnancy, and manage-
ment of patients with shunts and moderately elevated
pulmonary vascular resistance as well as perform a long-
term assessment of the “treat and repair” approach in
carefully selected subgroups. Finally, we urge that ran-
domized controlled trials assessing the benefits of PAH-
specific therapy should be extended to include less symp-
tomatic Eisenmenger patients, those with a pre-
Eisenmenger physiology with moderately elevated pulmo-
nary vascular resistance and those with a Fontan circula-
tion. Adoption of a standardized assessment approach for
Eisenmenger syndrome, as presented here and according to
the international guidelines, should be applied widely and
validated prospectively so that more patients with PAH
associated with CHD will benefit and reach their full life
potential.
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